New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials, demonstrating that concomitant use of Taltz and Zepbound maintained or further improved disease activity compared to Taltz alone. In the psoriasis trial, 40.5% of patients on the combination achieved complete skin clearance (PASI 100) at Week 52 versus 29.1% for monotherapy, while in the psoriatic arthritis trial, 43.7% achieved ACR50 versus 15.7% for monotherapy.
Key figures
- Drug Name
- Taltz (ixekizumab), Zepbound (tirzepatide)
- Phase Of Trial
- Phase 3b
- Acr50 taltz zepbound
- 43.7%
- Acr50 taltz monotherapy
- 15.7%
- Pasi 100 taltz zepbound
- 40.5%
- Pasi 100 taltz monotherapy
- 29.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.